A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Cinolazepam
Tepoxalin
The risk or severity of gastrointestinal irritation can be increased when Tepoxalin is combined with Hydrocortisone butyrate.
Cinolazepam
Azosemide
The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Azosemide.
Cinolazepam
Piretanide
The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Piretanide.
Cinolazepam
Aluminium phosphate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Aluminium phosphate.
Cinolazepam
Calcium silicate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Calcium silicate.
Cinolazepam
Aloglutamol
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Aloglutamol.
Cinolazepam
Aluminium glycinate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Aluminium glycinate.
Cinolazepam
Almasilate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Almasilate.
Cinolazepam
Magnesium peroxide
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Magnesium peroxide.
Cinolazepam
Hydrotalcite
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Hydrotalcite.
Cinolazepam
Aluminium acetoacetate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Aluminium acetoacetate.
Cinolazepam
Magnesium silicate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Magnesium silicate.
Cinolazepam
Magnesium trisilicate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Magnesium trisilicate.
Cinolazepam
Magnesium hydroxide
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Magnesium hydroxide.
Cinolazepam
Magaldrate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Magaldrate.
Cinolazepam
Calcium carbonate
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Calcium carbonate.
Cinolazepam
Aluminum hydroxide
The bioavailability of Hydrocortisone butyrate can be decreased when combined with Aluminum hydroxide.
Cinolazepam
GLPG-0492
The risk or severity of fluid retention can be increased when Hydrocortisone butyrate is combined with GLPG-0492.
Cinolazepam
Stanozolol
The risk or severity of fluid retention can be increased when Hydrocortisone butyrate is combined with Stanozolol.
Cinolazepam
Oxymetholone
The risk or severity of fluid retention can be increased when Hydrocortisone butyrate is combined with Oxymetholone.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3